We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00501657
Recruitment Status : Completed
First Posted : July 16, 2007
Last Update Posted : October 29, 2015
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Karen Jones, Royal Adelaide Hospital

July 13, 2007
July 16, 2007
October 29, 2015
July 2007
June 2008   (Final data collection date for primary outcome measure)
Gastric emptying rate [ Time Frame: 4 hours per study ]
Same as current
Complete list of historical versions of study NCT00501657 on ClinicalTrials.gov Archive Site
Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite [ Time Frame: 4 hours per study ]
Same as current
Not Provided
Not Provided
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to reduce the blood glucose (sugar) response to a meal and this may potentially be due to slowing of stomach emptying. This is particularly relevant to people who have diabetes, in whom normalization of elevated blood glucose levels is important to maintain health.

The purpose of this study is to evaluate the effect of sitagliptin on gastric emptying, intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects. Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of nutrients, and their absorption, across the small intestine. The rate of entry of carbohydrate into the small intestine is especially important in patients with diabetes mellitus. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesized that sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and diminish the glycemic response to, a carbohydrate-containing meal.

Fifteen healthy subjects (male and female) will be studied. Each subject will be studied on two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching placebo in a randomized, double blind, crossover design. Measurements of gastric emptying, intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will be measured for 4 hours following ingestion of a mashed potato meal.

Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Gastroparesis
  • Diabetes Mellitus
  • Drug: Sitagliptin
    100mg mane for 2 days
    Other Names:
    • MK-0431-075
    • Januvia
  • Drug: Placebo
    100mg mane for 2 days
  • Experimental: Sitagliptin (100mg)
    Active drug (sitagliptin)
    Intervention: Drug: Sitagliptin
  • Placebo Comparator: Placebo (sugar pill)
    Inactive drug (placebo)
    Intervention: Drug: Placebo
Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther. 2012 Aug;36(4):379-90. doi: 10.1111/j.1365-2036.2012.05198.x. Epub 2012 Jun 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2011
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female (females must be using an appropriate contraceptive method)
  • 18 - 45 years
  • Body mass index (BMI) 19 - 25 kg/m2.

Exclusion criteria:

  • Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or significant gastrointestinal symptoms
  • Subjects taking medication known to influence gastrointestinal function
  • Alcohol intake > 20 g per day
  • Smoking > 10 cigarettes per day
  • Pregnant and/or lactating females
  • Calculated creatinine clearance < 60 ml/min
  • Exposure to ionising radiation for research purposes in the previous 12 months.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Karen Jones, Royal Adelaide Hospital
Royal Adelaide Hospital
Merck Sharp & Dohme Corp.
Principal Investigator: Karen L Jones, PhD University of Adelaide, Royal Adelaide Hospital
Royal Adelaide Hospital
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP